Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
High-dose busulfan, melphalan and thiotepa as consolidation for noninflammatory high-risk breast cancer
Autore:
Gutierrez-Delgado, F; Holmberg, LA; Hooper, H; Appelbaum, FR; Livingston, RB; Maziarz, RT; Weiden, P; Rivkin, S; Montgomery, P; Kawahara, K; Bensinger, W;
Indirizzi:
Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA Univ Washington Seattle WA USA 98109 Canc Res Ctr, Seattle, WA 98109 USA Puget Sound Oncol Consortium, Seattle, WA USA Puget Sound Oncol Consortium Seattle WA USA Consortium, Seattle, WA USA
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 1, volume: 26, anno: 2000,
pagine: 51 - 59
SICI:
0268-3369(200007)26:1<51:HBMATA>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
STEM-CELL SUPPORT; BONE-MARROW TRANSPLANTATION; ADJUVANT CHEMOTHERAPY; STAGE-II; CLINICAL COURSE; POSITIVE NODES; AXILLARY NODES; PHASE-II; CYCLOPHOSPHAMIDE; DOXORUBICIN;
Keywords:
high-dose chemotherapy; breast cancer; PBSC; busulfan; melphalan; thiotepa;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
44
Recensione:
Indirizzi per estratti:
Indirizzo: Gutierrez-Delgado, F Univ Washington, Fred Hutchinson Canc Res Ctr, 1100 Fairview Av N D5-390,POB 19024, Seattle, WA 98109 USA Univ Washington 1100 Fairview Av N D5-390,POB 19024 Seattle WA USA 98109
Citazione:
F. Gutierrez-Delgado et al., "High-dose busulfan, melphalan and thiotepa as consolidation for noninflammatory high-risk breast cancer", BONE MAR TR, 26(1), 2000, pp. 51-59

Abstract

The purpose of this study was to evaluate the toxicity and efficacy of high-dose busulfan, melphalan and thiotepa (Bu/Mel/TT) in patients with high-risk noninflammatory breast cancer defined as stage II disease greater than or equal to 10 lymph nodes (n = 52) or stage III (n = 69), and prognostic factors for treatment outcome. One hundred and twenty-one patients (median age, 46 Sears) were treated with high-dose Bu (12 mg/kg), Mel (100 mg/m(2)) and TT (500 mg/m(2)) (HDC) followed by autologous stem cell infusion (ASCI). One hundred patients were initially treated with surgery followed by standard adjuvant chemotherapy prior to HDC/ASCI, Twenty-one patients with stage III disease had inoperable tumors at diagnosis and tr ere treated with neoadjuvant chemotherapy and surgery before HDC/ASCI. Transplant-related mortality was 6%. The probabilities of event-free survival (EFS) at 3 and 5 years (median follow-up of 36 months) from transplant mere, for all patients: 0.62-0.60; stage II: 0.71-0.67: stage III: 0.55-0.55 (for stage III adjuvant and neoadjuvant groups: 0.60-0.60 and 0.42-0.42, respectively). Multivariate analysis did not identify variables associated with poor outcome. The efficacy of Bu/Mel/TT is similar to other HDC regimens reported for patientswith high-risk non-inflammatory breast cancer. Bu/Mel/TT has high activityin stage II disease and a moderate benefit in stage III operable tumors.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 07:35:37